Core Viewpoint - The digital subtraction angiography system (DSA) uAngioAVIVA developed by United Imaging Healthcare has received FDA approval on April 28, making it the first and only domestic DSA device authorized for the U.S. market [1] Company Summary - United Imaging Healthcare has successfully developed a DSA system that meets FDA standards, indicating a significant achievement in the medical device sector [1] - The approval opens up new market opportunities for the company in the U.S., potentially increasing its market share and revenue [1] Industry Summary - The approval of a domestic DSA device highlights the growing capabilities of Chinese medical technology firms in competing in international markets [1] - This event may signal a shift in the competitive landscape of the medical imaging industry, as domestic products gain regulatory acceptance in major markets like the U.S. [1]